a major reason I am investedCytoDyn In the Running as

New Post Public Reply Private Reply Replies (1) Message Board
gbonation
596
a major reason I am investedCytoDyn In the Running as Trump's PrEP Replacement Plan

Prevention in HIV is all about keeping the viral load under 50 copies/mL, which the FDA considers an undetectable level and incapable of spreading the disease. As a once a week injectable, PRO 140 (leronlimab) offers convenience to the patient, virtually no side effects, and essentially keeps the virus away from the T-Cells and unable to replicate. Here's a nice analogy: HIV is like having little piranha in your blood that only eats T-Cells. The HAART treatment lets the piranha eat the T-Cell but slaughters most but not all of its offspring. Leronlimab, on the other hand, puts a Teflon coating around the T-Cells so the piranha have nothing to eat, so they die from malnutrition.

In a prevention setting, if a person at risk is given leronlimab and exposed to the virus the theory is that the virus will be blocked from replicating and eventually defenses in the body will break it down. This theory might even be applied to patients diagnosed with HIV. If this is done long enough perhaps the virus will eventually break down. Esteban Hernandez-Vargas said that " latently infected resting memory CD4+ T cells are the only cell type in which it has been clearly demonstrated that replication-competent virus can persist for several years in patients." Some patients have been on leronlimab for close to 5 years and at some point, this group of patients would be ideal for that sort analysis to see if they have in fact been cured.

The Thai Red Cross AIDS research center is initiating a PrEP clinical trial in subjects at high risk of HIV infection. Leading scientific advisor Dr. Jonah Sacha is conducting the research and CytoDyn has a Memorandum of Understanding with the Tai Red Cross to develop the HIV PrEP clinical trials. Sacha will also oversee the PrEP cure developments. Supporting PrEP and cure initiatives is the independent leronlimab data from the PRESTIGO Registry Study Group, which is to be presented at CROI. The people in this study are heavily treatment-experienced (HTE) patients that averaged at least 4-classes of drug resistance. The group of patients in this PrEP study are actually less sick than in the leronlimab phase 3 groups, where leronlimab managed to yield a whopping 90% responders rate. The PrEP responders rate to be announced at CROI might be very high. If the majority of HIV positive patients have no side effects, cannot transmit the disease, and has a fully functional immune system, this could be considered a functional cure, allowing Trump to claim a big win.

Gilead Maintains Dominance - But for How Long?

Throughout the article, little seeds have been planted to accentuate the case for a new player in HIV, who has a disruptive technology, backed by data on long term patients, who possibly could be cured with a drug that has little to no side effects. The CytoDyn story, once again, could be "too good to be true." However, the company is weeks away from a planned BLA submission that will result in a planned drug approval by June 2020, based on its rolling BLA and fast track status. In September, CytoDyn signed a non-binding licensing deal for $90 million from a major distributor. Once the drug is approved, the company has Samsung Biologics ready to provide them with up to $1.0 billion of inventory, based on anticipated drug prices, to meet the expected demand. CytoDyn also signed with distribution partners ready to market the drug. The pieces are in place for CytoDyn to start bringing in billions in revenue next year, except for one key thing. The company needs about $20 to $25 million to fund its operating costs while they are waiting for BLA approval over the next 6 months. This need for either a licensing deal or some type of financing seems to be dampening the enthusiasm for the technology as market participants await closure on financing terms or a licensing deal. It's been eerily quiet in the past two months because no big pharma company has made an even an overture toward what could be the most disruptive technology in the HIV space.

A Gilead investor might consider hedging his bets with the biggest threat in the HIV space. In a worst-case scenario for this investor, nothing happens and CytoDyn doesn't become a political football, then the investor can unwind the hedge after the CROI meeting. If something does happen then the hedge could be wildly profitable and even cover multiple situations included the licensing of the technology by a competitor. In all likelihood, the Trump lawsuit against Gilead could be much ado about nothing, as are most political events. However, can investors ignore 565 patients that were able to throw away their daily HAART regimen and defy big pharma? A 95% responder rate with prolonged remission and favorable safety is good enough to ignite a patient advocacy revolution, and as an investor, you don't want to be caught on the wrong side of the trade.

Investment Summary

There are a lot of theories floating out there about how to cure HIV and how to deal with the HIV epidemic. The big picture is that Trump seems stalwart in his approach about eradicating HIV, but therein lies the opportunity. The challenge to investors in the coming months leading up to the State of the Union is figuring out which horse is he going to back. Gilead is the largest HIV drug maker in the world and was the golden child in HIV until the Trump lawsuit hit. This lawsuit should serve notice to GILD investors that they have been targeted by Trump. There is a body of evidence to suggest that CytoDyn has the goods to be crowned the new innovator in HIV. It's definitely a long shot that Trump would elevate a $120 million market cap company as the frontrunner, but it is possible.

The most likely scenario would be Merck and ViiV jockeying for position in their efforts to get top billing and dethrone Gilead. Both of them could potentially negotiate with the administration, but its not clear which company might have the best strategy for PrEP. Whoever is perceived to have the inferior PrEP solution may be forced to seek a license from another PrEP drug maker; however, they would need a drug asset close to approval. Fortunately for CytoDyn, leronlimab approval is only about 6 months away, and if the technology is as robust as presented in this article, a licensee (Merck or ViiV) and CytoDyn could cobble together a viable PrEP program in months and then file for a label expansion.

If Gilead gets wind of this strategy, they might try to play "spoiler", which would be a great outcome for CytoDyn. Regardless, the bottom line is that Trump hit Gilead hard, and they could be on the ropes in the PrEP race. The question for investors is: does Gilead wake up in time to fight back, or does Merck, ViiV, or possibly a CytoDyn collaboration with one of them knock Gilead out?

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading